Safety, tolerability, and efficacy of fluoxetine as an antiviral for acute flaccid myelitis.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
30 04 2019
30 04 2019
Historique:
received:
05
06
2018
accepted:
10
10
2018
pubmed:
11
11
2018
medline:
19
12
2019
entrez:
11
11
2018
Statut:
ppublish
Résumé
To determine the safety, tolerability, and efficacy of fluoxetine for proven or presumptive enterovirus (EV) D68-associated acute flaccid myelitis (AFM). A multicenter cohort study of US patients with AFM in 2015-2016 compared serious adverse events (SAEs), adverse effects, and outcomes between fluoxetine-treated patients and untreated controls. Fluoxetine was administered at the discretion of treating providers with data gathered retrospectively. The primary outcome was change in summative limb strength score (SLSS; sum of Medical Research Council strength in all 4 limbs, ranging from 20 [normal strength] to 0 [complete quadriparesis]) between initial examination and latest follow-up, with increased SLSS reflecting improvement and decreased SLSS reflecting worsened strength. Fifty-six patients with AFM from 12 centers met study criteria. Among 30 patients exposed to fluoxetine, no SAEs were reported and adverse effect rates were similar to unexposed patients (47% vs 65%, Fluoxetine was well-tolerated. Fluoxetine was preferentially given to patients with AFM with EV-D68 identified and more severe paralysis at nadir, who ultimately had poorer long-term outcomes. This study provides Class IV evidence that for patients with EV-D68-associated AFM, fluoxetine is well-tolerated and not associated with improved neurologic outcomes.
Identifiants
pubmed: 30413631
pii: WNL.0000000000006670
doi: 10.1212/WNL.0000000000006670
pmc: PMC6512883
doi:
Substances chimiques
Antiviral Agents
0
Fluoxetine
01K63SUP8D
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2118-e2126Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002535
Pays : United States
Organisme : NINDS NIH HHS
ID : K23 NS101099
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS101208
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007210
Pays : United States
Informations de copyright
© 2018 American Academy of Neurology.
Références
Clin Infect Dis. 2016 Sep 15;63(6):737-745
pubmed: 27318332
Ann Neurol. 2016 Sep;80(3):326-38
pubmed: 27422805
Pediatr Neurol. 2016 Nov;64:94-98
pubmed: 27640319
J Child Neurol. 2014 Oct;29(10):1283-90
pubmed: 24453152
Antimicrob Agents Chemother. 2013 Apr;57(4):1952-6
pubmed: 23335743
J Infect Dis. 2017 Dec 5;216(10):1245-1253
pubmed: 28968718
JAMA Neurol. 2015 May;72(5):493-4
pubmed: 25775436
Euro Surveill. 2018 Jan;23(3):
pubmed: 29386095
Antiviral Res. 2016 Jul;131:61-5
pubmed: 27063860
J Clin Psychopharmacol. 2002 Dec;22(6):568-75
pubmed: 12454556
Neurology. 2017 Jul 11;89(2):129-137
pubmed: 28615421
Am J Psychiatry. 2002 May;159(5):755-60
pubmed: 11986128
Antimicrob Agents Chemother. 2015 Dec;59(12):7779-81
pubmed: 26149998
Lancet. 2015 Apr 25;385(9978):1662-71
pubmed: 25638662
J Neuropsychiatry Clin Neurosci. 1993 Summer;5(3):322-9
pubmed: 8369643
Clin Infect Dis. 2007 Oct 15;45(8):950-7
pubmed: 17879907
MMWR Morb Mortal Wkly Rep. 2014 Oct 10;63(40):901-2
pubmed: 25299607
Antimicrob Agents Chemother. 2015 Dec;59(12):7782-5
pubmed: 26369972
Neuropsychopharmacology. 2005 Aug;30(8):1576-83
pubmed: 15886723
JAMA. 2015 Dec 22-29;314(24):2663-71
pubmed: 26720027
Brain. 2010 Oct;133(10):2838-44
pubmed: 20928945
Lancet Infect Dis. 2018 Aug;18(8):e239-e247
pubmed: 29482893